Premier Alternatives

GPN Vaccines

Canberra, Australia · Founded 2017 · Privately Held (backing)

Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen. GPN Vaccines is based in Canberra, Australia and was founded in 2017. Its last reported valuation was $300 million in Jun 2024. It has raised $27.7 million across 1 recorded round; the latest was a $3.5 million seed round in Dec 2025.

Last reported valuation
$300.0M
Oct 2026
Priced at
—
Total raised
$27.7M
Last round
Seed Round
Dec 2025

GPN Vaccines key facts

as of Oct 2026
  • Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen.
  • GPN Vaccines is valued at approximately $300.0M as of Oct 2026 (last reported valuation).
  • It has raised $27.7M across 1 recorded rounds; the latest was Seed Round ($3.5M) in Dec 2025.
  • Notable investors include Shearwater Capital, Brandon Biocatalyst, Forepont Capital Partners, Kern Capital, Mike Gregg — 7 tracked in total.
  • GPN Vaccines has filed 1 Form D with the SEC, most recently Jan 2026 ($3.5M sold to 63 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$300.0M

GPN Vaccines's last reported valuation, Jun 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of GPN Vaccines with a free account
  • ·Watch GPN Vaccines: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

GPN Vaccines funding rounds

1 rounds
Dec 2025Seed Round$3.5MSEC filing▮
Full funding history →

GPN Vaccines valuation

GPN Vaccines's last reported valuation was $300 million in Jun 2024. No priced round, secondary trade or fund mark has surfaced since.

How much has GPN Vaccines raised?

GPN Vaccines has raised $27.7 million in total; 1 of its rounds is on record. The largest on record was a $3.5 million seed round in Dec 2025.

GPN Vaccines has filed 1 Form D with the SEC, most recently in Jan 2026 ($3.5 million sold to 63 investors).

GPN Vaccines investors

7 investors are on record for GPN Vaccines, including Shearwater Capital, Brandon Biocatalyst, Forepont Capital Partners and Kern Capital. The seed round in Dec 2025 drew 63 investors.

About GPN Vaccines

Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen. The company's vaccine is developed by using a gamma-irradiation process that inactivates and kills the bacteria while leaving the surface protein antigens intact, thereby conferring improved immunity against Streptococcus pneumoniae, giving patients the chance of improved immunity against Streptococcus pneumoniae.

Sector
Healthcare
HQ
Canberra, Australia
Founded
2017
Employees
28
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.